Metagenomi Therapeutics Inc (MGX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.80 is considered Undervalued compared with the five-year average of -1.29. The fair price of Metagenomi Therapeutics Inc (MGX) is between 8.22 to 10.24 according to relative valuation method. Compared to the current price of 1.53 USD , Metagenomi Therapeutics Inc By Undervalued By 81.4%.

Relative Value

Fair Zone

8.22-10.24

Current Price：1.53

81.4%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Metagenomi Therapeutics Inc (MGX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Metagenomi Therapeutics Inc (MGX) has a current Price-to-Book (P/B) ratio of 0.35. Compared to its 3-year average P/B ratio of 0.40, the current P/B ratio is approximately -11.15% higher. Relative to its 5-year average P/B ratio of 0.40, the current P/B ratio is about -11.15% higher. Metagenomi Therapeutics Inc (MGX) has a Forward Free Cash Flow (FCF) yield of approximately -147.43%. Compared to its 3-year average FCF yield of -110.05%, the current FCF yield is approximately 33.97% lower. Relative to its 5-year average FCF yield of -110.05%, the current FCF yield is about 33.97% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MGX competitors is 59.94, providing a benchmark for relative valuation. Metagenomi Therapeutics Inc Corp (MGX.O) exhibits a P/S ratio of 2.80, which is -95.33% above the industry average. Given its robust revenue growth of -24.80%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MGX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MGX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MGX currently overvalued or undervalued?

Metagenomi Therapeutics Inc (MGX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.80 is considered Undervalued compared with the five-year average of -1.29. The fair price of Metagenomi Therapeutics Inc (MGX) is between 8.22 to 10.24 according to relative valuation method. Compared to the current price of 1.53 USD, Metagenomi Therapeutics Inc is Undervalued By 81.40%.

What is Metagenomi Therapeutics Inc (MGX) fair value?

MGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Metagenomi Therapeutics Inc (MGX) is between 8.22 to 10.24 according to relative valuation method.

How does MGX's valuation metrics compare to the industry average?

The average P/S ratio for MGX's competitors is 59.94, providing a benchmark for relative valuation. Metagenomi Therapeutics Inc Corp (MGX) exhibits a P/S ratio of 2.80, which is -95.33% above the industry average. Given its robust revenue growth of -24.80%, this premium appears unsustainable.

What is the current P/B ratio for Metagenomi Therapeutics Inc (MGX) as of Mar 03 2026?

As of Mar 03 2026, Metagenomi Therapeutics Inc (MGX) has a P/B ratio of 0.35. This indicates that the market values MGX at 0.35 times its book value.

What is the current FCF Yield for Metagenomi Therapeutics Inc (MGX) as of Mar 03 2026?

As of Mar 03 2026, Metagenomi Therapeutics Inc (MGX) has a FCF Yield of -147.43%. This means that for every dollar of Metagenomi Therapeutics Inc's market capitalization, the company generates -147.43 cents in free cash flow.

What is the current Forward P/E ratio for Metagenomi Therapeutics Inc (MGX) as of Mar 03 2026?

As of Mar 03 2026, Metagenomi Therapeutics Inc (MGX) has a Forward P/E ratio of -0.67. This means the market is willing to pay $-0.67 for every dollar of Metagenomi Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Metagenomi Therapeutics Inc (MGX) as of Mar 03 2026?

As of Mar 03 2026, Metagenomi Therapeutics Inc (MGX) has a Forward P/S ratio of 2.80. This means the market is valuing MGX at $2.80 for every dollar of expected revenue over the next 12 months.

MGX Valuation